PE 22-28 10 mg

PE 22-28 10 mg contains a spadin-derived heptapeptide studied as a selective TREK-1 potassium channel blocker. In preclinical research, it has been investigated for rapid antidepressant-like effects, hippocampal neurogenesis, and synaptogenesis support. It is not FDA-approved for any human use, and no human clinical trials have been conducted.

No human dosing protocol exists for PE 22-28. In rodent studies, the compound was administered via intraperitoneal injection at 3–4 mcg/kg/day for 4 days. Community protocols commonly reference 100–400 mcg per day administered subcutaneously or intranasally, with morning dosing preferred. These figures are anecdotal and not medically established.

No. PE 22-28 is not HPTA-active and does not suppress the hypothalamic-pituitary-gonadal axis. Post-cycle therapy in the context of testosterone recovery is not applicable. Community protocols typically reference a 4-week minimum off-period between cycles.

PE 22-28 selectively blocks TREK-1 potassium channels with high potency (IC50 ~0.12 nM). TREK-1 channels generate background leak currents that suppress neuronal excitability in serotonergic pathways. By blocking these channels, PE 22-28 increases serotonergic neuron firing and serotonin release, producing antidepressant-like effects in rodent models within 4 days.

In rodent studies, antidepressant-like effects were observed within 4 days of daily treatment, with a duration of action up to 23 hours per dose. Human timeframes are unknown because no human studies have been conducted. Any extrapolation from rodent behavioral models to humans is speculative.

There is no evidence-based “best” antidepressant peptide. PE 22-28 is studied for TREK-1 blockade, while Semax is investigated for BDNF upregulation and Selank for GABAergic anxiolytic effects. The appropriate choice depends on research goals, and all non-medical use falls outside approved indications.

Spadin is a 17-amino-acid peptide, while PE 22-28 is a shortened 7-amino-acid fragment of spadin. PE 22-28 is approximately 300–500x more potent at TREK-1 (IC50 ~0.12 nM vs 40–60 nM) and has a longer duration of action (~23 hours vs ~7 hours).

PE 22-28 blocks TREK-1 potassium channels to enhance serotonergic neurotransmission, while Semax is a synthetic ACTH fragment studied for BDNF upregulation and cognitive enhancement through melanocortin receptor activation. The two have different mechanisms and are sometimes referenced together in cognitive stacks.

100 mcg is a conservative starting point in community protocols. No human dosing has been established, so the appropriate amount cannot be determined from clinical data. The 10 mg vial contains 10,000 mcg total, providing multiple doses depending on the protocol.

PE 22-28 10 mg is labeled at 10 mg of PE 22-28 per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.

No published laboratory report is currently available for this specific product. Product potency and purity verification would apply to tested samples only and should not be interpreted as a measurement of every vial or production batch.

Lyophilized PE 22-28 is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.